Literature DB >> 15674398

Effects of blocking urokinase receptor signaling by antisense oligonucleotides in a mouse model of experimental prostate cancer bone metastases.

F Margheri1, S D'Alessio, S Serratí, M Pucci, F Annunziato, L Cosmi, F Liotta, R Angeli, A Angelucci, G L Gravina, N Rucci, M Bologna, A Teti, B Monia, G Fibbi, M Del Rosso.   

Abstract

An important factor implicated in tumor cell predisposition for invasion and metastasis is the malignancy-related upregulation of urokinase plasminogen activator receptor (uPAR). uPAR signals by activating different tyrosine kinases in different cells. We examined the effects of inhibiting uPAR signaling by inhibition of uPAR expression with antisense oligonucleotides (aODNs) in PC3 human prostate cancer cells and evaluated aODN effect in a mouse model of prostate cancer bone metastasis. Following uPAR aODN treatment, PC3 cells exhibited a strong decrease in uPAR expression, evaluated by flow cytometry and by polymerase chain reaction, and of FAK/JNK/Jun phosphorylation. The synthesis of cyclins A, B, D1 and D3 was inhibited, as shown by Western blotting, flow cytometry and polymerase chain reaction, and PC3 cells accumulated in the G2 phase of the cell cycle. PC3 cells' adhesion was unaffected, while proliferation and invasion of Matrigel were impaired. A total of 60 mice were subjected to intracardiac injection of PC3 cells and were randomly assigned to three groups: aODN (treated with 0.5 mg intraperitoneum/mouse/day), dODN (treated with the same amounts of a degenerated ODN) and control (injected with a saline solution). At 28 days after heart injection, mice were subjected to a digital scan of total body radiography, which revealed 80% reduction in mice affected by bone metastasis. The use of uPAR aODNs produced a substantial prophylactic effect against prostate cancer bone metastasis, which has to be ascribed to downregulation of uPAR expression.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15674398     DOI: 10.1038/sj.gt.3302456

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  23 in total

1.  An anti-urokinase plasminogen activator receptor antibody (ATN-658) blocks prostate cancer invasion, migration, growth, and experimental skeletal metastasis in vitro and in vivo.

Authors:  Shafaat A Rabbani; Bushra Ateeq; Ani Arakelian; Maria Luisa Valentino; David E Shaw; Lisa M Dauffenbach; Christopher A Kerfoot; Andrew P Mazar
Journal:  Neoplasia       Date:  2010-10       Impact factor: 5.715

Review 2.  Nonreceptor tyrosine kinases in prostate cancer.

Authors:  Yu-Ming Chang; Hsing-Jien Kung; Christopher P Evans
Journal:  Neoplasia       Date:  2007-02       Impact factor: 5.715

3.  Modulation of prostate cancer cell gene expression by cell-to-cell contact with bone marrow stromal cells or osteoblasts.

Authors:  Shuming Zhang; Jun Wang; Mehmet A Bilen; Sue-Hwa Lin; Samuel I Stupp; Robert L Satcher
Journal:  Clin Exp Metastasis       Date:  2009-09-29       Impact factor: 5.150

4.  Spontaneous lung and lymph node metastasis in transgenic breast cancer is independent of the urokinase receptor uPAR.

Authors:  Kasper Almholt; Ole Didrik Lærum; Boye Schnack Nielsen; Ida Katrine Lund; Leif Røge Lund; John Rømer; Annika Jögi
Journal:  Clin Exp Metastasis       Date:  2015-06-04       Impact factor: 5.150

5.  Targeting MMP-9, uPAR, and cathepsin B inhibits invasion, migration and activates apoptosis in prostate cancer cells.

Authors:  A K Nalla; B Gorantla; C S Gondi; S S Lakka; J S Rao
Journal:  Cancer Gene Ther       Date:  2010-05-07       Impact factor: 5.987

6.  RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo.

Authors:  Sai MuraliKrishna Pulukuri; Christopher S Gondi; Sajani S Lakka; Aman Jutla; Norman Estes; Meena Gujrati; Jasti S Rao
Journal:  J Biol Chem       Date:  2005-08-26       Impact factor: 5.157

7.  uPAR antibody (huATN-658) and Zometa reduce breast cancer growth and skeletal lesions.

Authors:  Niaz Mahmood; Ani Arakelian; Haseeb Ahmed Khan; Imrana Tanvir; Andrew P Mazar; Shafaat A Rabbani
Journal:  Bone Res       Date:  2020-04-17       Impact factor: 13.567

Review 8.  Urokinase and its receptors in chronic kidney disease.

Authors:  Guoqiang Zhang; Allison A Eddy
Journal:  Front Biosci       Date:  2008-05-01

9.  Systemic sclerosis-endothelial cell antiangiogenic pentraxin 3 and matrix metalloprotease 12 control human breast cancer tumor vascularization and development in mice.

Authors:  Francesca Margheri; Simona Serratì; Andrea Lapucci; Chillà Anastasia; Betti Giusti; Marco Pucci; Eugenio Torre; Francesca Bianchini; Lido Calorini; Adriana Albini; Agostina Ventura; Gabriella Fibbi; Mario Del Rosso
Journal:  Neoplasia       Date:  2009-10       Impact factor: 5.715

10.  Inactivation of uPA and its receptor uPAR by 3,3'-diindolylmethane (DIM) leads to the inhibition of prostate cancer cell growth and migration.

Authors:  Aamir Ahmad; Dejuan Kong; Sanila H Sarkar; Zhiwei Wang; Sanjeev Banerjee; Fazlul H Sarkar
Journal:  J Cell Biochem       Date:  2009-06-01       Impact factor: 4.429

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.